103 related articles for article (PubMed ID: 23375235)
1. Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours.
Prestat E; de Morais SR; Vendrell JA; Thollet A; Gautier C; Cohen PA; Aussem A
Comput Biol Med; 2013 May; 43(4):334-41. PubMed ID: 23375235
[TBL] [Abstract][Full Text] [Related]
2. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.
Krig SR; Miller JK; Frietze S; Beckett LA; Neve RM; Farnham PJ; Yaswen PI; Sweeney CA
Oncogene; 2010 Oct; 29(40):5500-10. PubMed ID: 20661224
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
4. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line.
Sun G; Zhou J; Yin A; Ding Y; Zhong M
Int J Oncol; 2008 May; 32(5):1065-71. PubMed ID: 18425333
[TBL] [Abstract][Full Text] [Related]
5. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
Littlepage LE; Adler AS; Kouros-Mehr H; Huang G; Chou J; Krig SR; Griffith OL; Korkola JE; Qu K; Lawson DA; Xue Q; Sternlicht MD; Dijkgraaf GJ; Yaswen P; Rugo HS; Sweeney CA; Collins CC; Gray JW; Chang HY; Werb Z
Cancer Discov; 2012 Jul; 2(7):638-51. PubMed ID: 22728437
[TBL] [Abstract][Full Text] [Related]
6. Prognosis and gene expression profiling of 20q13-amplified breast cancers.
Ginestier C; Cervera N; Finetti P; Esteyries S; Esterni B; Adélaïde J; Xerri L; Viens P; Jacquemier J; Charafe-Jauffret E; Chaffanet M; Birnbaum D; Bertucci F
Clin Cancer Res; 2006 Aug; 12(15):4533-44. PubMed ID: 16899599
[TBL] [Abstract][Full Text] [Related]
7. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad.
Quinlan KG; Verger A; Yaswen P; Crossley M
Biochim Biophys Acta; 2007 Jun; 1775(2):333-40. PubMed ID: 17572303
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
9. Analysis of lifestyle and metabolic predictors of visceral obesity with Bayesian Networks.
Aussem A; Tchernof A; de Morais SR; Rome S
BMC Bioinformatics; 2010 Sep; 11():487. PubMed ID: 20920208
[TBL] [Abstract][Full Text] [Related]
10. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction.
Huang G; Krig S; Kowbel D; Xu H; Hyun B; Volik S; Feuerstein B; Mills GB; Stokoe D; Yaswen P; Collins C
Hum Mol Genet; 2005 Nov; 14(21):3219-25. PubMed ID: 16203743
[TBL] [Abstract][Full Text] [Related]
11. [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].
Li J; Zhong M; Song LL; Su GD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):824-5. PubMed ID: 16793610
[TBL] [Abstract][Full Text] [Related]
12. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
[TBL] [Abstract][Full Text] [Related]
14. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Thollet A; Vendrell JA; Payen L; Ghayad SE; Ben Larbi S; Grisard E; Collins C; Villedieu M; Cohen PA
Mol Cancer; 2010 Nov; 9():291. PubMed ID: 21059223
[TBL] [Abstract][Full Text] [Related]
15. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells.
Nonet GH; Stampfer MR; Chin K; Gray JW; Collins CC; Yaswen P
Cancer Res; 2001 Feb; 61(4):1250-4. PubMed ID: 11245413
[TBL] [Abstract][Full Text] [Related]
16. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.
Cohen PA; Donini CF; Nguyen NT; Lincet H; Vendrell JA
Oncotarget; 2015 Dec; 6(39):41566-81. PubMed ID: 26431164
[TBL] [Abstract][Full Text] [Related]
17. [Expression of ZNF217 in human ovarian cystadenocarcinoma and its clinical significance].
Sun GQ; Zhong M; Ding YQ; Su GD; Song TR; Yin AL
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):685-8. PubMed ID: 19403395
[TBL] [Abstract][Full Text] [Related]
18. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.
Garcia MJ; Pole JC; Chin SF; Teschendorff A; Naderi A; Ozdag H; Vias M; Kranjac T; Subkhankulova T; Paish C; Ellis I; Brenton JD; Edwards PA; Caldas C
Oncogene; 2005 Aug; 24(33):5235-45. PubMed ID: 15897872
[TBL] [Abstract][Full Text] [Related]
19. Advances to Bayesian network inference for generating causal networks from observational biological data.
Yu J; Smith VA; Wang PP; Hartemink AJ; Jarvis ED
Bioinformatics; 2004 Dec; 20(18):3594-603. PubMed ID: 15284094
[TBL] [Abstract][Full Text] [Related]
20. The candidate oncogene ZNF217 is frequently amplified in colon cancer.
Rooney PH; Boonsong A; McFadyen MC; McLeod HL; Cassidy J; Curran S; Murray GI
J Pathol; 2004 Nov; 204(3):282-8. PubMed ID: 15476264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
